Following our previous cell line studies (Qu et al., 2010a; Qu et al., 2010b; Sun et al., 2015; Yan et al., 2009b; Vanoirbeek et al., 2014; Yan et al., 2009a; Fu et al., 2010), we have established the PDZ-LIM domain-containing protein PDLIM2, also known as SLIM or mystique (Torrado et al., 2004; Tanaka et al., 2005; Loughran et al., 2005), as a bona fide tumor suppressor and its repression as a causative driver of lung cancer and resistance to ICIs and chemotherapeutic agents (Sun et al., 2019). Here, PDLIM2 is linked to lung cancer.